NCT03176719

Brief Summary

It has long been recognized that the positive effects of vaccination on childhood mortality cannot be solely attributed to a decline in the disease targeted by the vaccine. These so-called non-specific effects of vaccination have so far mostly been linked to mortality. However, it has been suggested that non-specific effects may also effect morbidity and nutritional status. This study aims to further explore the correlation between vaccination, susceptibility to infectious diseases (particularly malaria and bacterial infections), nutritional status and immunity. With this prospective cross sectional study among healthy individuals in rural west-Africa we aim to address several research questions at the same time. This study will assess the influence of (time-point of) vaccination on morbidity, mortality and immune status among healthy individuals in a rural sub-Saharan African setting. Secondly, to explore the prevalence of subclinical malaria, iron deficiency anemia, sickle cell anemia and thallasemia among a healthy rural sub-Saharan African population. And finally to assess normal hemocytometry values among a healthy rural sub-Saharan African population.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,005

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2017

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 18, 2017

Completed
18 days until next milestone

First Posted

Study publicly available on registry

June 5, 2017

Completed
12 days until next milestone

Study Start

First participant enrolled

June 17, 2017

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2017

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2018

Completed
Last Updated

September 4, 2018

Status Verified

August 1, 2018

Enrollment Period

5 months

First QC Date

May 18, 2017

Last Update Submit

August 31, 2018

Conditions

Outcome Measures

Primary Outcomes (8)

  • Vaccination data

    Vaccination data as recorded on the vaccination card

    June 2017 - December 2017

  • Nutritional status (Z-score or BMI)

    weight (kg), height (cm) and upperarm circumference (mm) leading to outcome measure on nutritional status: as appropriate Z-score or BMI

    June 2017 - December 2017

  • History of disease

    Recorded history of disease according to the participants health card

    June 2017 - December 2017

  • Immunological profile

    Cytokine levels, including IL-1b, IL-6, IL-10, IFN-gamma, TNF-alpha and IL-17, which will be assessed through ELISA. Measurement will be done on stimulated and unstimulated blood. Ex-vivo whole blood stimulation will be done with RPMI, LPS, MTB, Staphylococcus aureus, Candida albicans and Salmonella Typhimurium.

    June 2017 - December 2017

  • Genetic immunological profile

    DNA analysis to assess genetic variations determining pro- versus anti inflammatory response including mTOR, HK2, PFKP, GLS, and GLUD1/2.

    June 2017 - December 2017

  • subclinical parasitemia

    low level malaria infection detected by SYSMEX hematology analyzer XN - 30

    June 2017 - December 2017

  • Anemia

    Differentiation of different forms of anemia using SYSMEX hematology analyzers XN -20 and XN - 30

    June 2017 - December 2017

  • Reference values for hemocytometry in a healthy rural population from Burkina Faso

    Hemocytometry using SYSMEX hematology analyzers XN -20 and XN - 30

    June 2017 - December 2017

Secondary Outcomes (1)

  • Gametocyte PCR

    June 2017 - December 2017

Other Outcomes (1)

  • Salmonella PCR

    June 2017 - December 2017

Study Arms (5)

Children of 1 years old

200 healthy volunteers aged between 12 and 23 months

Other: Venipuncture

Children aged 2-4

200 healthy volunteers aged between 24 and 59 months

Other: Venipuncture

Children aged 5 - 9

200 healthy volunteers aged between 60 and 119 months

Other: Venipuncture

Children aged 10 - 14

200 healthy volunteers aged between 120 and 179 months

Other: Venipuncture

Adults of 15 years and older

200 healthy volunteers of 180 months or older

Other: Venipuncture

Interventions

1. Full blood count and leukocyte differentiation. 2. Detection of malaria parasites and parasite differentiation to trophozoites, gametocytes and ringstages (XN-30) 3. Detection of anemia, thallasemia and sickle cell anemia (XN-20) 4. Ex-vivo stimulation of wholeblood with various stimuli. Read-out will be a spectrum of cytokines (ELISA) 5. Circulating cytokines and inflammatory markers (ELIZA) 6. DNA analysis to assess genetic variations determining pro- versus anti inflammatory response including mTOR, HK2, PFKP, GLS, and GLUD1/2. 7. pan-Salmonella PCR 8. Gametocyte PCR

Adults of 15 years and olderChildren aged 10 - 14Children aged 2-4Children aged 5 - 9Children of 1 years old

Eligibility Criteria

Age1 Year+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A total of 5 groups will be selected. Each age group will consist of 220 participant (including 20% for potential non response). The survey will be conducted among 24 villages. Demographic age distribution is comparable for each of the villages. In order to prevent bias, a proportionate number of participants will be selected from each village based on its total population. Participants will then be randomly selected from each sample stratum using systematic selection.

You may qualify if:

  • Healthy participants currently living in the Nanoro HDSS area, born before May 2016.

You may not qualify if:

  • Current febrile illness,
  • Current chronic illnesses, HIV, TB, renal failure, cardiac disease (if known)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinical Research Unit of Nanoro

Nanoro, Boulkiemedé, Burkina Faso

Location

Related Publications (1)

  • Kabore B, Post A, Berendsen MLT, Diallo S, Lompo P, Derra K, Rouamba E, Jacobs J, Tinto H, de Mast Q, van der Ven AJ. Red blood cell homeostasis in children and adults with and without asymptomatic malaria infection in Burkina Faso. PLoS One. 2020 Nov 30;15(11):e0242507. doi: 10.1371/journal.pone.0242507. eCollection 2020.

Biospecimen

Retention: SAMPLES WITH DNA

EDTA blood and heparizined blood

MeSH Terms

Conditions

AnemiaMalaria, Falciparum

Interventions

Phlebotomy

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic DiseasesMalariaProtozoan InfectionsParasitic DiseasesInfectionsMosquito-Borne DiseasesVector Borne Diseases

Intervention Hierarchy (Ancestors)

Blood Specimen CollectionSpecimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesTherapeuticsSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • André van der Ven, Prof. Dr.

    Radboud University Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 18, 2017

First Posted

June 5, 2017

Study Start

June 17, 2017

Primary Completion

October 31, 2017

Study Completion

December 31, 2018

Last Updated

September 4, 2018

Record last verified: 2018-08

Data Sharing

IPD Sharing
Will not share

Locations